8-K: CooperCompanies Q4 Beats, New Board Chair Appointed

CooperCompanies announced strong fiscal Q4 and full-year 2025 results, exceeding expectations, alongside the appointment of Colleen E. Jay as the new Board Chair, effective January 2, 2026.

Summary

• Fourth quarter 2025 revenue reached $1,065.2 million, marking a 5% increase (3% organically).
• Fiscal year 2025 revenue totaled $4.1 billion, up 5% (4% organically).
• Fourth quarter 2025 GAAP diluted earnings per share (EPS) was $0.43, a 27% decrease, while non-GAAP diluted EPS rose 11% to $1.15.
• Fiscal year 2025 GAAP diluted EPS was $1.87, down 4%, but non-GAAP diluted EPS increased 12% to $4.13.
• The company closed fiscal 2025 ahead of consensus revenue, earnings, and free cash flow expectations.
• Significant reorganization and integration activities in Q4 resulted in approximately $89 million in charges but are expected to generate annual pre-tax savings of $50 million starting fiscal 2026.
• The company repurchased $197.3 million of common stock (approximately 2.9 million shares) in Q4 2025 and $290.1 million (approximately 4.1 million shares) for the full fiscal year.
• The Board expanded the share repurchase program by $1 billion in September, bringing the total authorization to $2 billion, with nearly $1 billion remaining.
• Fiscal year 2026 guidance was initiated, projecting total revenue of $4,299 $4,338 million (4.5% to 5.5% organic growth) and non-GAAP diluted EPS of $4.45 $4.60.
• An updated long-term free cash flow objective of more than $2.2 billion from fiscal 2026 through fiscal 2028 was announced.
• Robert S. Weiss resigned as Chairman of the Board, effective January 2, 2026, but will continue to serve as a Board member.
• Colleen E. Jay was appointed as the new Chairman of the Board, effective January 2, 2026.
• A formal strategic review has been initiated to identify opportunities to enhance long-term shareholder value, including potential partnerships, joint ventures, divestitures, mergers, and other transactions.

Sentiment

Score: 8

Explanation: The company reported strong fiscal 2025 results, exceeding consensus expectations for revenue, earnings, and free cash flow. It provided optimistic 2026 guidance above expectations, driven by successful reorganization and strong performance in key segments. The strategic review and expanded share repurchase program further enhance positive sentiment, despite a temporary dip in GAAP EPS due to one-time charges.

Positives

• Closed fiscal 2025 ahead of consensus revenue, earnings, and free cash flow expectations.
• Achieved eight consecutive quarters of earnings beats.
• New fiscal 2026 guidance is above expectations, supported by successful Q4 reorganization activity.
• Reorganization efforts are expected to yield annual pre-tax savings of approximately $50 million beginning in fiscal 2026.
• Improved cash flow momentum, with an updated long-term free cash flow objective of more than $2.2 billion from fiscal 2026 through 2028.
• CooperVision is building momentum with MyDay contract wins and MiSight revenue up 37% in Q4.
• CooperSurgical finished the year strong, delivering revenue at the high end of guidance, with optimism for a stronger fertility business in 2026.
• The share repurchase program was expanded by $1 billion, with nearly $1 billion remaining available for additional repurchases.
• Colleen E. Jay, with a strong track record in global operational leadership and strategic execution, was appointed as the new Board Chair.

Negatives

• Fourth quarter 2025 GAAP diluted EPS decreased 27% to $0.43.
• Fiscal year 2025 GAAP diluted EPS decreased 4% to $1.87.
• GAAP gross margin for Q4 2025 was 61%, down from 67% in the prior year, primarily due to costs related to reorganization activity.
• Non-GAAP gross margin for Q4 2025 was down 70 basis points from the prior year to 66%, primarily due to tariffs and mix.
• GAAP operating margin for Q4 2025 was 13%, down from 19% in the prior year, driven by costs related to reorganization activity.
• Reorganization and integration activity resulted in approximately $89 million in cash and non-cash charges during Q4 2025.

Risks

• Adverse changes in global or regional general business, political, and economic conditions, including uncertainty and instability of certain countries, man-made or natural disasters, and pandemic conditions.
• The impact of international conflicts and the global response on the global and local economy, financial markets, energy markets, currency rates, and the ability to supply product.
• Challenges of managing substantial and expanding international operations and complying with a variety of legal, compliance, and regulatory requirements.
• The actual imposition or threats of tariffs, customs duties, and fees by the U.S. government and other nations, and other retaliatory actions.
• Foreign currency exchange rate and interest rate fluctuations, including the risk of decreases in net sales and earnings.
• Impact of existing and future variable rate indebtedness and associated interest expense due to rate increases.
• Changes in tax laws, examinations by tax authorities, and changes in the geographic composition of income.
• Acquisition-related adverse effects, including failure to achieve anticipated benefits, integration delays or costs, and issues with regulatory approvals.
• Compliance costs and potential liability in connection with U.S. and foreign laws and healthcare regulations pertaining to privacy and security of personal information (e.g., HIPAA, CCPA, GDPR), including data security breaches.
• Major disruptions in the operations of manufacturing, accounting, financial reporting, research and development, or distribution facilities due to integration challenges, disasters, pandemics, cybersecurity incidents, or third-party vendor failures.
• A successful cybersecurity attack which could interrupt or disrupt information technology systems or cause the loss of confidential data.
• Market consolidation of large customers globally resulting in a larger proportion or concentration of business being derived from fewer customers.
• Disruptions in supplies of raw materials, particularly components used to manufacture silicone hydrogel lenses.
• New U.S. and foreign government laws and regulations, and changes in existing laws, affecting the healthcare industry, including the EU Medical Devices Regulation (MDR) and the EU In Vitro Diagnostic Medical Devices Regulation (IVDR).
• Legal costs, insurance expenses, settlement costs, and the risk of an adverse decision, prohibitive injunction, or settlement related to product liability, patent infringement, contractual disputes, or other litigation.
• Limitations on sales following product introductions due to poor market acceptance.
• New competitors, product innovations or technologies, and competitors' expansion through acquisitions.
• Reduced sales, loss of customers, reputational harm, and costs from product recalls and warning letters.
• Failure to receive, or delays in receiving, regulatory approvals or certifications for products.
• Failure of customers and end users to obtain adequate coverage and reimbursement from third-party payers for products and services.
• The requirement to provide for a significant liability or to write off, or accelerate depreciation on, a significant asset, including goodwill, other intangible assets, and idle manufacturing facilities and equipment.
• The success of research and development activities and other start-up projects.
• Dilution to earnings per share from acquisitions or issuing stock.
• Impact and costs incurred from changes in accounting standards and policies.
• Risks related to environmental laws and requirements applicable to facilities, products, or manufacturing processes, including evolving regulations regarding hazardous substances.
• Risks related to environmental, social, and corporate governance (ESG) issues, including regulatory and disclosure requirements, climate change, and sustainability.

Future Outlook

The company initiated fiscal year 2026 financial guidance, projecting total revenue between $4,299 million and $4,338 million (4.5% to 5.5% organic growth) and non-GAAP diluted EPS of $4.45 to $4.60. It also updated its long-term free cash flow objective to over $2.2 billion from fiscal 2026 through 2028, driven by improved profitability and cash generation from successful Q4 reorganization activities. A formal strategic review is underway to identify opportunities to simplify the business and unlock long-term value, including potential partnerships, joint ventures, divestitures, mergers, and other transactions. CooperVision anticipates upcoming product launches globally, and CooperSurgical expects a much stronger year for its fertility business in 2026.

Management Comments

• "We closed fiscal 2025 ahead of consensus revenue, earnings, and free cash flow expectations, and we enter 2026 with clear priorities to drive long-term shareholder value: accelerating top-line growth, improving profitability, accelerating cash generation, and continuing share repurchases." Al White, President and CEO.
• "CooperVision is building momentum with MyDay contract wins, with MiSight up 37% in Q4, and with upcoming product launches rolling out globally." Al White, President and CEO.
• "CooperSurgical also finished the year strong delivering revenue at the high end of our guidance, and were optimistic that 2026 will be supported by a much stronger year for our fertility business." Al White, President and CEO.
• "Our disciplined execution has delivered eight consecutive quarters of earnings beats, and our new guidance is above expectations supported by successful Q4 reorganization activity." Al White, President and CEO.
• "Importantly, these efforts are translating into improved cash flow, and we expect this momentum to continue with updated guidance of more than $2.2 billion in free cash flow from 2026 through 2028. This positions us to fund share repurchases, reduce debt and pursue strategic investments that reinforce our commitment to long-term shareholder returns." Al White, President and CEO.
• "Bob's vision, industry knowledge, and leadership have been key to our success. I'm deeply grateful for his commitment and look forward to continuing our work together." Al White, President and CEO.
• "I'm also thrilled the Board appointed Colleen as Chair. Her track record of driving growth through global operational leadership, transformational innovation, strategy and execution make her a fantastic choice for this role." Al White, President and CEO.

Industry Context

CooperCompanies operates in the global medical device sector, with its CooperVision unit focusing on contact lenses and CooperSurgical on fertility and women's health. The strong performance in CooperVision, particularly with MiSight and new contract wins, suggests a robust demand for advanced vision care solutions. The optimism for CooperSurgical's fertility business in 2026 indicates potential recovery or growth in the fertility market, which can be influenced by healthcare access and demographic trends. The company's emphasis on operational efficiency, cost reduction through reorganization, and a formal strategic review aligns with broader industry trends where medical device companies are optimizing their portfolios and operations to enhance shareholder value in a competitive and evolving regulatory landscape.

Comparison to Industry Standards

• The company closed fiscal 2025 ahead of consensus revenue, earnings, and free cash flow expectations, indicating outperformance relative to market analyst projections.
• The achievement of eight consecutive quarters of earnings beats demonstrates consistent outperformance against internal or market expectations, suggesting strong operational execution.
• The filing does not provide specific comparable companies, projects, or results for direct benchmarking against industry peers.

Management Changes

Corporate Governance

Legal Proceedings

• Charges in the three months ended October 31, 2025, included $2.9 million related to legal matters.
• Charges in the twelve months ended October 31, 2025, included $5.9 million related to legal matters.
• The company identifies legal costs, insurance expenses, settlement costs, and the risk of adverse decisions related to product liability, patent infringement, contractual disputes, or other litigation as potential future challenges.

Stakeholder Impact

• Shareholders: Likely positive impact due to exceeding financial expectations, strong future guidance, an expanded share repurchase program, and a strategic review aimed at unlocking long-term value. This could lead to increased share price.
• Employees: Reorganization activities resulted in employee severance costs, indicating workforce adjustments for operational efficiency.
• Customers: CooperVision's momentum with new contract wins and product launches suggests continued innovation and service in vision care. CooperSurgical's optimism for its fertility business implies ongoing support for women's health and fertility services.
• Creditors: Improved financial health, evidenced by lower average debt and interest expense, combined with strong free cash flow generation, enhances the company's ability to service its debt obligations.

Next Steps

• Colleen E. Jay will assume the role of Chairman of the Board, effective January 2, 2026.
• Robert S. Weiss will stand for reelection as a Board member at the Company's 2026 Annual Meeting of Stockholders.
• The company expects to focus capital deployment on repurchasing shares under the recently announced $2 billion share repurchase program.
• A formal strategic review will continue to identify opportunities to simplify the business and unlock long-term value, including through partnerships, joint ventures, divestitures, mergers, business combinations, and other transactions.
• CooperVision has upcoming product launches rolling out globally.
• CooperSurgical anticipates a much stronger year for its fertility business in 2026.

Key Dates

Recommendation

The company has demonstrated consistent outperformance, beating earnings expectations for eight consecutive quarters and closing fiscal 2025 ahead of consensus for revenue, earnings, and free cash flow. The initiated fiscal 2026 guidance is also above expectations, supported by successful reorganization efforts that are projected to yield $50 million in annual pre-tax savings. The updated long-term free cash flow objective of over $2.2 billion through 2028, coupled with an expanded $2 billion share repurchase program, signals robust capital allocation and a strong commitment to shareholder returns. The formal strategic review further indicates a proactive approach to optimizing the business and unlocking value. While GAAP EPS saw a temporary dip due to reorganization charges, the underlying non-GAAP performance and future outlook are robust, making this an attractive investment opportunity.

Keywords

CooperCompanies, COO, Financial Results, Earnings, Q4 2025, Full Year 2025, Fiscal 2026 Guidance, Medical Device, Contact Lenses, Fertility, Women's Health, CooperVision, CooperSurgical, EPS, Revenue, Free Cash Flow, Share Repurchase, Board of Directors, Chairman Change, Strategic Review, Corporate Governance